Condition
Monoclonal Gammopathy of Renal Significance
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Recruiting2
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06083922Phase 2Recruiting
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
NCT06418477Phase 2RecruitingPrimary
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
NCT05119309CompletedPrimary
MGRS: Clinical-histological Features of a Multicenter Case Series
NCT03629561UnknownPrimary
Diagnosis of MGRS in Patients With Paraproteinemias: Clinical, Anatomopathological and Pathophysiological Study
Showing all 4 trials